Kirill Peskov - Concepedia

Author

Kirill Peskov

Also Known As

K V Peskov, K. Peskov, K. V. Peskov, K.V. Peskov, KIRILL PESKOV, Kirill Peskov, Kirill V Peskov, Kirill V. Peskov, Novartis Pharma, Peskov, Kirill

Publications

935

Citations

H-Index

Concepts

All Affiliations

Sechenov University AstraZeneca (United States)AstraZeneca (Sweden)InSysBio (Russia)Lomonosov Moscow State University

About

Kirill Peskov is an author at Sechenov University specializing in medicine, microbiology, and systems biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	43
2	Biochemistry	2	2	25
3	Natural Sciences	1	1	12
4	Social Sciences	1	1	13
5	Diabetes	1	1	13

Kirill Peskov

Publications

580

Citations

H-Index

Page 1

	Year	Citations
Radiation and PD-(L)1 treatment combinations: immune response and dose optimization via a predictive systems model Yuri Kosinsky, Simon J. Dovedi, Kirill Peskov, Journal for ImmunoTherapy of Cancer	2018	107
Kinetic modelling of central carbon metabolism in <i>Escherichia coli</i> Kirill Peskov, Ekaterina A. Mogilevskaya, Oleg Demin FEBS Journal	2012	56
Agent Based Modeling of Human Gut Microbiome Interactions and Perturbations Tatiana Shashkova, Anna Popenko, Alexander Tyakht, PLoS ONE	2016	53
DBSolve Optimum: a software package for kinetic modeling which allows dynamic visualization of simulation results Nail Gizzatkulov, Igor Goryanin, Evgeny Metelkin, BMC Systems Biology	2010	46
A Physiology-Based Model of Bile Acid Distribution and Metabolism Under Healthy and Pathologic Conditions in Human Beings Veronika Voronova, Victor Sokolov, Amani Al-Khaifi, Cellular and Molecular Gastroenterology and Hepatology	2020	45
Differentiating the Sodium‐Glucose Cotransporter 1 Inhibition Capacity of Canagliflozin vs. Dapagliflozin and Empagliflozin Using Quantitative Systems Pharmacology Modeling Victor Sokolov, Tatiana A. Yakovleva, Lulu Chu, CPT Pharmacometrics & Systems Pharmacology	2020	38
Comparison of the urinary glucose excretion contributions of SGLT2 and SGLT1: A quantitative systems pharmacology analysis in healthy individuals and patients with type 2 diabetes treated with SGLT2 inhibitors Tatiana A. Yakovleva, Victor Sokolov, Lulu Chu, Diabetes Obesity and Metabolism	2019	35
Longitudinal Tumor Size and Neutrophil‐to‐Lymphocyte Ratio Are Prognostic Biomarkers for Overall Survival in Patients With Advanced Non‐Small Cell Lung Cancer Treated With Durvalumab S. V. Gavrilov, Kirill Zhudenkov, Gabriel Helmlinger, CPT Pharmacometrics & Systems Pharmacology	2020	27
Role of T Cell-To-Dendritic Cell Chemoattraction in T Cell Priming Initiation in the Lymph Node: An Agent-Based Modeling Study Ivan Azarov, Kirill Peskov, Gabriel Helmlinger, Frontiers in Immunology	2019	24
Comparative quantitative systems pharmacology modeling of anti-PCSK9 therapeutic modalities in hypercholesterolemia Victor Sokolov, Gabriel Helmlinger, Catarina Nilsson, Journal of Lipid Research	2019	21

Page 1